GrowLife Inc (PHOT)

[big-yank]

PHOT's Marketing Group needs a total overhaul. Co-sponsoring events with NRML is so passe and is like an embarrassing throwback to High Times centerfold of glam-photo'd marijuana plants. Who can ever forget that purple-gold layout of Maui Wowie?

Maybe these clowns should quit looking for bell-bottom jeans in retro shoppes, get a haircut and take a page from the NRA by lobbying for medical marijuana treatment in a sophisticated and organized way, planning to add decriminalization opportunties such as in Colorado as the social objections continue to break down across America.

Masquerading behind some "blah-blah" crappola about growing hydroponic tomatoes with PHOT "technology" is just totally embarrassing and obscures the potential future which is HUGE. This company is about growing marijuana. Its products were primarily developed to hide indoor production from the DEA, reminiscent of the moonshine stills of a bygone era, but the legal climate is shifting... for better or for worse... and the opportunity is too large here to obscure with rubbish.

What's next? A co-partnership with Disney to co-sponsor The Land exhibit at Epcot by growing eggplants? C'mon, guys, get serious.

I am personally NOT a stoner and I really am somewhat averse to the "herb" as you guys like to conveniently describe it, but from a pure investor perspective this stock has huge upside. If it is marketed legitimately, within legal boundaries, and can offer some serious medical and cost-to-treatment benefits vs. so many over-prescribed/abused opiate Rx's that are far more ruinous to America's social fabric, it could have an enormously welcoming entry into modern pharmacopeia.

Understand this... the DEA would much rather deal with non-addictive abuse of cannabis oil vs. the hugely addictive evil of oxycontin/oxycodone/percoset, et al, and all the associated crime that flows from opiate abuse. PHOT could actually help resolve a lot of the drug cartel influence on America, simply by restrategizing how it promotes its business.

PHOT will either get smarter about how it runs its business, or another pharmaceutical house will overrun their niche and sieze the moment.

All IMO.